Navigation Links
Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
Date:1/19/2010

scalating doses and maintenance treatment over a number of years. During the trial investigators will 'challenge' the volunteers with house dust mite allergens to assess the therapeutic effect of Circassia's T-cell vaccine.

"The start of these two studies demonstrates the rapid clinical advance of Circassia's T-cell vaccines. With this further broadening of our portfolio, Circassia now has three development programmes in phase II, targeting some of the most common allergies in the world," said Steve Harris, Circassia's CEO. "We are committed to continuing this rapid pace of development, to ensure we can bring these breakthrough T-cell vaccines to market as soon as possible. We believe that patients can benefit greatly from our ToleroMune allergy therapies, which offer the prospect of simple, convenient and effective treatment while minimising the risk of the severe and sometimes life-threatening side effects associated with many existing immunotherapies."

About Circassia's allergy T-cell vaccines

Circassia's range of allergy T-cell vaccines is based on its proprietary ToleroMune(R) technology. This technology utilises allergen epitopes to generate regulatory T cells that suppress allergic immune responses. Clinical results with Circassia's cat allergy T-cell vaccine show that short treatment regimes can greatly reduce patients' symptoms, without the need for adjuvants or other immune stimulators, while proving extremely well tolerated. As a result, the company's allergy T-cell vaccines offer major potential clinical benefits compared with existing therapies, and consequently have significant market opportunities. Over 150 million people suffer from allergic rhinitis in the US and Europe, and the current treatment market is approximately $12 billion per year.

ToleroMune technology has additional potentia
'/>"/>

SOURCE Circassia Ltd
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Circassia Raises GBP15 Million ($25 Million) in Oversubscribed Investment Round
2. Circassia Begins Phase II Clinical Trial With Ragweed Allergy Therapy
3. Circassias Allergy Therapy Begins Phase II Clinical Trial in Asthma Patients
4. Circassia Completes Patient Recruitment for Phase II Clinical Trial of Toleromune(R) Allergy Treatment
5. Circassia Initiates Further Phase II Clinical Study of Toleromune(R) Anti-Allergy Technology
6. Circassia Achieves Successful Phase II Clinical Results With Toleromune(R) Anti-Allergy Technology
7. Cadence Pharmaceuticals Announces FDA Extends New Drug Application Review for Intravenous Acetaminophen by Three Months
8. Applied Seals North America Extends Global Network With Addition of Distributor in Europe
9. Lincare Holdings Inc. Extends Terms of Employment Agreements with Executive Officers
10. Neurosciences Institute Discovers Drug Extends Stroke Treatment Time to 24 Hours, Repairs Brain Tissue
11. FDA Extends Review Period for Daiichi Sankyo, Lilly Investigative Antiplatelet Drug, Prasugrel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... 3, 2015  VA North Texas Health Care ... of vBloc, a technology-based, scientifically advanced weight loss ... implant called the Maestro® Rechargeable System that intermittently ... messages involving food intake and processing between the ... and customizable to meet the needs of a ...
(Date:6/3/2015)... , June 3, 2015  SurgiQuest®, Inc. ... access technologies for minimally invasive surgery (MIS) announced ... System in over 250,000 procedures.  Adoption has risen ... over last year, driven by the company,s expansion ... well as geographic expansion to over 45 countries.   ...
(Date:6/3/2015)... DUBLIN , June 02, 2015 ... the addition of the "Global Neurodegenerative Diseases ... The global neurodegenerative diseases market to grow ... 2014-2019. This report covers the present ... neurodegenerative diseases market for the period 2015-2019. To ...
Breaking Medicine Technology:VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 2VA North Texas First VA in the Country to Perform vBloc Implant, a Cutting-Edge Weight Loss Therapy 3Rapid Procedure Growth With SurgiQuest's AirSeal System 2Global Neurodegenerative Diseases Market 2015-2019 - Reformulation of Marketed Drugs 2
(Date:6/3/2015)... MD (PRWEB) June 03, 2015 On the ... a $13 billion industry by 2020 ( click here ... Markets), computer scientists believe Baltimore has the talent ... industry in which genetic code and other biological data are ... cure disease. “Baltimore contains all the elements of a ...
(Date:6/3/2015)... (PRWEB) June 03, 2015 Array ... exchange technology, has announced that CEO Jonathan Rickert will ... 2015 on June 4, 2015. The session will ... technologies are disrupting traditional business models in health care, ... value. , WHAT: Digital Transformation and the Health ...
(Date:6/3/2015)... Justina Molzon, MS Pharm, JD will ... upcoming Annual Meeting. DIA’s Global Inspire Award program recognizes ... excellence, and commitment to service on a global scale. ... Service Award that recognizes the “Member of the Year” ... and who has contributed to the advancement of DIA’s ...
(Date:6/3/2015)... The panel of independent experts has spent weeks considering ... the awards presented tonight at TU-Automotive Detroit 2015. , ... best-of-the-best can now be revealed as: , Car Maker ... rivals aside by taking the coveted Car Maker of ... panel of expert judges., Stand out comments included: ...
(Date:6/3/2015)... 2015 According to an article published ... intercepted fake oxycodone pills which actually contained the potent ... look legitimate, and even sported the “A/215” imprint common ... consuming 30 mg oxycodone to be exceptionally critical of ... buy them illegally on the street. Fentanyl is an ...
Breaking Medicine News(10 mins):Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Array Health’s CEO to Present at America’s Health Insurance Plans Institute 2015 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 2Health News:Former FDA Official and U.S. Public Health Service Officer to Be Honored with Global Inspire Award at DIA’s 2015 51st Annual Meeting 3Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 2Health News:Fake Oxycodone Pills of Fentanyl Discovered in Tennessee by Police 3
... patients, study finds , MONDAY, March 8 (HealthDay News) ... they catch it early, but a new study suggests ... risk of developing the disease. , If their ophthalmologists ... in the eye won,t need to take prescription anti-glaucoma ...
... if parent had brain attack by 65, chances of same ... -- If your mother or father had a stroke by ... a stroke by that age are increased fourfold, U.S. researchers ... such as high blood pressure, obesity and smoking. These risks ...
... Virologists surprised to ... to be reactivated to an infectious form. , ... TAMPA, FL (PRWEB) February 20, 2010 -- Human herpesvirus 6 ... lasts for the rest of a person’s life. In a study funded by the ...
... , ... ... ... ...
... ... ... ... ...
... ... ... , ... , , ...
Cached Medicine News:Health News:Waiting Safe for Some at Risk of Glaucoma 2Health News:Stroke Risk Runs in the Family 2Health News:Stroke Risk Runs in the Family 3Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 2Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 3Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 4Health News:Infectious Virus Hides In Human Chromosomes During Latency And Can Be Passed From Parents To Their Children, 5Health News:Chicago AIDS Advocates Launch Female Condom Campaign 2Health News:Chicago AIDS Advocates Launch Female Condom Campaign 3Health News:Chicago AIDS Advocates Launch Female Condom Campaign 4Health News:Chicago AIDS Advocates Launch Female Condom Campaign 5Health News:Chicago AIDS Advocates Launch Female Condom Campaign 6Health News:Chicago AIDS Advocates Launch Female Condom Campaign 7Health News:Chicago AIDS Advocates Launch Female Condom Campaign 8Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 2Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 3Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 4Health News:SCAN Health Plan Debuts the First Mobile Resource Center Built Specifically for Seniors 5Health News:Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts 2Health News:Highmark and its Employees Donate $161,686 for Haiti Disaster Relief Efforts 3
Exactech's AcuMatch C-Series (Cemented Femoral Stem) is designed to provide solutions to the problems which compromise both the short and long term successful outcome of cemented hip arthroplasty....
The Precedent establishes a new generation of revision hip stems....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Calcar replacement stems provide options for revision and trochanteric fractures. Revision hip surgery and trauma often require prosthetic designs that replace proximal medial calcar bone loss....
Medicine Products: